1505515-69-4
Chemical Structure
Taletrectinib
Synonym(s): DS-6051b; AB-106; IBI-344
- CAS No.: 1505515-69-4
- Formula:C29H34FN5O5
- Molecular Weight:551.61
IUPAC Name: 3-(4-((R)-2-aminopropoxy)phenyl)-N-((R)-1-(3-fluorophenyl)ethyl)imidazo[1,2-b]pyridazin-6-amine adipate
InChIKey: DORJQZDOULKINH-QNBGGDODSA-N
SMILES: O=C(O)CCCCC(O)=O.C[C@@H](NC1=NN2C(C=C1)=NC=C2C3=CC=C(OC[C@H](N)C)C=C3)C4=CC=CC(F)=C4
Biological Activity: Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Taletrectinib | 99.63% | Taletrectinib (DS-6051b) is a potent, orally active, and next-generation selective ROS1/NTRK inhibitor. Taletrectinib potently inhibits recombinant ROS1, NTRK1, NTRK2, and NTRK3 with IC50s of 0.207, 0.622, 2.28, and 0.98 nM, respectively. Taletrectinib also inhibits ROS1 G2032R and other Crizotinib-resistant ROS1 mutants. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.84
HY-131003ATaletrectinib free base -
Similarity Score 0.56
HY-186147SGI-1776-amide-C6-acid -
Similarity Score 0.56
HY-13277IRAK inhibitor 3 -
Similarity Score 0.54
HY-13276IRAK inhibitor 2 -
Similarity Score 0.53
HY-120179LP-922761 -
Similarity Score 0.52
HY-110350CHR-6494 TFA -
Similarity Score 0.50
HY-123141K00135 -
Similarity Score 0.50
HY-13287ASGI-1776 -
Similarity Score 0.49
HY-13287SGI-1776 free base -
Explore the MedChemAI to find more analogs
References
- [1]. Katayama R, et al. The new-generation selective ROS1/NTRK inhibitor DS-6051b overcomes crizotinib resistant ROS1-G2032R mutation in preclinical models. Nat Commun. 2019;10(1):3604. Published 2019 Aug 9. [Content Brief]
- [2]. Fujiwara Y, et al. Safety and pharmacokinetics of DS-6051b in Japanese patients with non-small cell lung cancer harboring ROS1 fusions: a phase I study. Oncotarget. 2018;9(34):23729-23737. Published 2018 May 4. [Content Brief]
